Venom-derived peptides that block the KV1.3 potassium channel show therapeutic potential in autoimmune diseases, with one analog already completing Phase 1 clinical trials.
Phase 1 completeDalazatide, a sea anemone venom peptide analog, has completed Phase 1 clinical trials for psoriasis
What the researchers found
Venom-derived KV1.3 inhibitors show efficacy in animal models of multiple autoimmune diseases, and the ShK analog dalazatide has completed Phase 1 trials for psoriasis.
Why it matters
KV1.3 is upregulated in the specific immune cells driving autoimmune diseases, making targeted peptide inhibitors a precision medicine approach with potentially fewer side effects than broad immunosuppression.
The numbers in context
Dalazatide Phase 1 complete; efficacy in RA, psoriasis, MS models; KV1.3 target for IBD, AD, PD, fibrosis
How the study worked
Narrative review of venom peptide pharmacology, KV1.3 biology in autoimmune disease, and clinical development progress.
Who was studied
Review covering preclinical models and Phase 1 clinical trial participants
What this study cannot tell us
Most efficacy data from animal models. Only dalazatide has reached clinical trials. Brain penetration remains a challenge for neuroinflammatory applications.
How to read the evidence
Review citing animal model efficacy data and one Phase 1 clinical trial. Promising but most applications are preclinical.
When this study was published
Published in 2020. KV1.3-targeted therapies continue to be developed.
The bigger picture
The expanding list of conditions where KV1.3 is a target, combined with the growing library of venom-derived inhibitors, suggests this class of peptide therapeutics will continue to advance toward clinical use.
Questions still open
- Will dalazatide advance to Phase 2/3 trials?
- Can venom peptides be modified for brain penetration to treat neuroinflammatory diseases?
- Which autoimmune disease is the best initial clinical target for KV1.3 inhibitors?
Common questions
How do venom peptides treat autoimmune diseases?
What is dalazatide?
Read the original research
The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides.
Biochemical pharmacology, 181, 114146
Citation
Tajti, Gabor; Wai, Dorothy C C; Panyi, Gyorgy; Norton, Raymond S. (2020). The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides.. Biochemical pharmacology, 181, 114146. https://doi.org/10.1016/j.bcp.2020.114146